Stockchase Opinions

Joshua Varghese Alexandria Real Estate Equities ARE-N PAST TOP PICK Dec 05, 2018

(A Top Pick Aug 16/18, Down 3%) They hold assets in all the major US campuses. They are the curators of new biotech and big pharma real estate start-ups on and near these campuses. When a lease comes due, they can raise rents 30% or more.
N/A

Stock price when the opinion was issued

REAL ESTATE
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK

They specialize in technology and life-sciences clusters. Their tenants will be repatriation cash, so ARE's partnership with these tenants will create value and rent growth. (2.9% dividend yield)

TOP PICK
The entry point is great right now. They look to double their revenues by 2022 from $900 million today. They have a great balance sheet and management team. They hold assets in all the major US campuses. They are the curators of new biotech and big pharma real estate start-ups on and near these campuses. When a lease comes due, they can raise rents 30% or more. Yield 3%. (Analysts’ price target is $138.25)
PAST TOP PICK
(A Top Pick Dec 05/18, Up 16%) They are a stellar company with a stellar management team. They are the dominant player of campuses to life sciences companies. It is important for these companies to be together to share ideas in an ecosystem. They have a free cash flow growth of north of 10%. He sees the company growing with their valuation. It is still a compelling investment opportunity.
PAST TOP PICK
(A Top Pick Aug 16/18, Up 24%) One of the best capital compounders out there. They build life sciences buildings on campuses across the US. Biotech companies co-locate on these campuses, creating great opportunities. The fundamentals remain positive and he continues to hold it.
PAST TOP PICK
(A Top Pick Dec 05/18, Up 33%) When he called it, ARE wasn't cheap. They hold life sciences properties, which is solid and lucrative (fuelled by R&D spending). They can raise rents by 20-30% annually with these companies, which means strong cash flow growth.
TOP PICK
The only REIT in health sciences, and is benefiting from demand to treat and cure COVID-19 and other diseases. Though considered an office REIT, she notes that many of its tenants cannot work from home. Rent collection is impressive at 99%, because life sciences are deemed essential. It leased 1 million sq. feet in Q2, consistent with prior quarters with rents 15% higher. Likes its assets, and it's a niche way to play this sector. (Analysts’ price target is $181.56)
BUY
Admires the management, but he doesn't like commercial office space now, but ARE's tenants are American biotech and life science companies, which carry the costs of. A lot of value here.
DON'T BUY

The largest US office REIT. Used to own it, still likes it alot for owning specialized spaces, like labs for biotechs. But this niche has problems, lacking IPOs and new companies. Is down 20% YTD.